Research analysts at Cantor Fitzgerald decreased their FY2025 earnings per share estimates for Beam Therapeutics in a note issued to investors on Wednesday, February 26th. Cantor Fitzgerald analyst R.
Xometry (NASDAQ:XMTR – Free Report) had its target price upped by Cantor Fitzgerald from $12.00 to $20.00 in a research note issued to investors on Wednesday morning,Benzinga reports. The brokerage ...
We recently compiled a list of the 10 Best Stocks Under $50 to Buy Right Now. In this article, we are going to take a look at ...
As an enterprise engaged in the development, manufacturing and commercialization of specialty plasma-derived therapeutics, ...
In a report released today, Daniel Ives from Wedbush maintained a Buy rating on SoundHound AI, Inc Class A (SOUN – Research Report), with a ...
Each Unit Includes One Class A Ordinary Share andOne Share Right to Receive 1/10th of a Class A Ordinary Share New York, NY, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Fifth Era Acquisition Corp. I (the "Compa ...